Clinical trial
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)
NCT02158858 is registered in ClinicalTrials.gov with Constellation Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)
- Lead sponsor
- Constellation Pharmaceuticals
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- July 16, 2014
- Completion date
- January 9, 2025
- Enrollment
- 336 (actual)
- Sites
- 48
Conditions
As the registry lists them; a condition with its own page is linked.
bone marrow disease, essential thrombocytosis, hematological disease, leukemia, leukemia, myelocytic, acute, myelodysplastic syndrome (mds), myelodysplastic/myeloproliferative neoplasm, myelofibrosis, myeloproliferative disorders, neoplasms, neoplasms by histologic type, precancerous conditions, preleukemia, primary myelofibrosis